These biopharm stocks have a general pattern of surging ahead upon the approval of their drugs, after which the general public joins in. However, they soon become impatient, and the stock falters. Finally, as the company approaches profitability, the stock has its strongest appreciation. I believe that's where we are with MDVN now. The quarterly report demonstrated that they have executed the introduction of Xtandi flawlessly. Only the misguided expectation of Schmidt, the Cowen analyst, that they would quickly gain off-label use among urologists held it back briefly.